Abstract:Conventional adenomas are initiated by APC gene mutation that activates the WNT signal. Serrated neoplasia is commonly initiated by BRAF or KRAS mutation. WNT pathway activation may also occur, however, to what extent this is owing to APC mutation is unknown. We examined aberrant nuclear β-catenin immunolocalization as a surrogate for WNT pathway activation and analyzed the entire APC gene coding sequence in serrated and conventional pathway polyps and cancers. WNT pathway activation was a common event in conventional pathway lesions with aberrant nuclear immunolocalization of β-catenin and truncating APC mutations in 90% and 89% of conventional adenomas and 82% and 70% of BRAF wild-type cancers, respectively. WNT pathway activation was seen to a lesser extent in serrated pathway lesions. It occurred at the transition to dysplasia in serrated polyps with a significant increase in nuclear β-catenin labeling from sessile serrated adenomas (10%) to sessile serrated adenomas with dysplasia (55%) and traditional serrated adenomas (9%) to traditional serrated adenomas with dysplasia (39%) (P=0.0001). However, unlike the conventional pathway, truncating APC mutations were rare in the serrated pathway lesions especially sessile serrated adenomas even when dysplastic (15%) and in the BRAF mutant cancers with microsatellite instability that arise from them (8%). In contrast, APC missense mutations that were rare in conventional pathway adenomas and cancers (3% in BRAF wild-type cancers) were more frequent in BRAF mutant cancers with microsatellite instability (32%). We conclude that increased WNT signaling is important in the transition to malignancy in the serrated pathway but that APC mutation is less common and the spectrum of mutations is different than in conventional colorectal carcinogenesis. Moderate impact APC mutations and non-APC-related causes of increased WNT signaling may have a more important role in serrated neoplasia than the truncating APC mutations common in conventional adenomas.

Wnt signaling and colon carcinogenesis: Beyond APC

Adenomatous polyposis coli in cancer and therapeutic implications

Targeting the Wnt signaling pathway in colorectal cancer

Transcriptional Regulation of Wnt/β-Catenin Pathway in Colorectal Cancer

Wnt/β-catenin Singal Transduction Pathway and Colorectal Cancer

To Wnt or Lose: the Missing Non-Coding Linc in Colorectal Cancer

Wnt signaling in colorectal cancer: pathogenic role and therapeutic target

APC controls Wnt-induced β-catenin destruction complex recruitment in human colonocytes

Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC

The Wnt signaling pathway: a potential therapeutic target against cancer

Wnt/β-Catenin Signaling Pathway in the Development and Progression of Colorectal Cancer

Dysregulation and crosstalk of cellular signaling pathways in colon carcinogenesis.

Chromatin-associated APC Regulates Gene Expression in Collaboration with Canonical WNT Signaling and AP-1.

The Interplay among Wnt/β-catenin Family Members in Colorectal Adenomas and Surrounding Tissues

Wnt signaling in cancer

Wnt signaling in cell adhesion, development, and colon cancer

The role of APC in WNT pathway activation in serrated neoplasia

Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy

Wnt signalling in the mouse intestine

Altered lipid metabolism in APC-driven colorectal cancer: the potential for therapeutic intervention

Mechanism of APC truncation involved in colorectal cancer tumorigenesis (Review)